Customs valuation requires proof of price influence; unsupported related-party allegations and proforma invoices cannot displace declared import values.
Cross-objections under the Customs Act may challenge any adverse part of an order once an appeal is filed, not merely the appellant's grounds. Declared import values cannot be rejected without evidence of a statutory related-party relationship, price influence, additional consideration, or excess remittance; proforma invoices, relationships among persons behind separate entities, and consultancy or investment payments are insufficient. Post-import redetermination of retail sale price lacked statutory machinery for the relevant period, and undisclosed invoices prejudiced the importer's defence. A transdermal foot patch intended for therapeutic relief and improved circulation is classifiable as a medicament, not a skin-care preparation. Consequential undervaluation, confiscation and penalty findings lack foundation.
Issues: (i) Whether the respondent's cross-objections could challenge adverse portions of the order beyond the limited grounds raised in the Revenue's appeals; (ii) Whether the declared import values could be rejected on the basis of alleged control by the Malaysian entity, related-party relationship, parallel/proforma invoices, and alleged excess foreign-exchange remittances; (iii) Whether the revised retail sale price basis for additional customs duty was sustainable; (iv) Whether ConyTakara was classifiable as a medicament under CTH 3004 or as a skin-care preparation under CTH 3304.
Issue (i): Whether the respondent's cross-objections could challenge adverse portions of the order beyond the limited grounds raised in the Revenue's appeals.
Analysis: Section 129A(4) of the Customs Act, 1962 permits a respondent, notwithstanding that it has not independently appealed, to file cross-objections against any part of an order once an appeal against that order is filed. Such cross-objections must be disposed of as an appeal. The provision is not confined to rebutting only the grounds set out in the opposing party's appeal.
Conclusion: The cross-objections were maintainable and could challenge the substantive adverse findings in the impugned order.
Issue (ii): Whether the declared import values could be rejected on the basis of alleged control by the Malaysian entity, related-party relationship, parallel/proforma invoices, and alleged excess foreign-exchange remittances.
Analysis: No evidence established that shares were allotted to, or that administrative or financial control over the importer was exercised by, Conybio Malaysia. The alleged parallel invoices were proforma invoices and were unsupported by evidence of flowback or remittance exceeding the declared invoice values. The Malaysian suppliers and the Indian importer, being distinct juridical entities, could not be treated as family members under Rule 2(2)(viii) of the Customs Valuation Rules, 1988 merely because of relationships among their directors or shareholders. Nor was any other statutory basis for related-party treatment or proof that a relationship influenced price established. Consultancy payments were found to relate to services rendered and investment earnings could not be treated as additional import consideration.
Conclusion: Rejection of the declared transaction values and the consequential undervaluation demand were unsustainable, in favour of the assessee.
Issue (iii): Whether the revised retail sale price basis for additional customs duty was sustainable.
Analysis: The documentary invoices allegedly forming the basis for revised retail sale prices were not supplied to the importer, causing prejudice to its defence. Further, for the relevant pre-01.03.2008 period, no statutory machinery existed under Section 3(2) of the Customs Tariff Act, 1975 for post-import redetermination of the retail sale price of imported goods.
Conclusion: The additional customs duty demand based on revised retail sale prices was unsustainable, in favour of the assessee.
Issue (iv): Whether ConyTakara was classifiable as a medicament under CTH 3004 or as a skin-care preparation under CTH 3304.
Analysis: ConyTakara was a transdermal foot patch intended to provide therapeutic relief, detoxification and improved blood circulation. Its primary character was curative rather than cosmetic or for enhancement of appearance. The product therefore fell within the scope of medicaments, including transdermal administration systems, and did not satisfy the description of beauty or skin-care preparations.
Conclusion: ConyTakara is classifiable as a medicament under CTH 3004 and not under CTH 3304, in favour of the assessee.
Final Conclusion: The findings supporting undervaluation, related-party influence, retail sale price-based assessment, confiscability, and penalty lacked legal and evidentiary foundation; consequential relief follows.
Ratio Decidendi: Declared import value cannot be displaced on suspicion arising from proforma invoices, familial links between persons behind separate corporate entities, or unrelated remittances, without legally cognisable related-party status and evidence of additional consideration influencing the import price.